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Abstract
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a
panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines. In vitro, sorafenib
significantly decreased cell proliferation and phosphorylation levels of MAPK and PI3K/Akt pathways while increased
apoptotic cell death. In vivo, sorafenib treatment resulted in a cytostatic rather than cytotoxic effect on tumor cell growth
associated with a limited inhibition of tumor volumes. However, sorafenib induced an average 50% reduction of tumor
vessel density and a 2-fold increase of necrotic areas. Upon sorafenib treatment, endothelial and tumor cells from SU-DHL-
4V, Granta-519, and KMS-11 nodules showed a potent inhibition of either phospho-ERK or phospho-AKT, whereas a
concomitant inhibition of phospho-ERK and phospho-AKT was only observed in HD-MyZ nodules. In conclusion, sorafenib
affects the growth of lymphoid cell lines by triggering antiangiogenic mechanism(s) and directly targeting tumor cells.
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Introduction
Sorafenib is an oral multitargeted inhibitor of kinases approved
by the Food and Drug Administration for the treatment of patients
with advanced renal cell carcinoma (RCC) and those with
unresectable hepatocellular carcinoma (HCC) [1–3]. It is also
approved by the European Medicines Agency for the treatment of
patients with HCC and patients with advanced RCC with whom
prior interferon-a- or interleukin-2-based therapy had failed or
those considered to be unsuitable for such therapy. Sorafenib is
currently undergoing phase II/III clinical evaluation in a wide
variety of other solid as well as hematopoietic tumors [4–7].
In addition to targeting the receptor tyrosine kinases c-kit, Flt3,
and RET [8,9], sorafenib at a clinically achievable plasma
concentration of 10 mM, inhibits multiple additional receptor
tyrosine kinases and intracellular kinases [10]. By inhibiting the
Raf/mitogen-activated protein (MAP)/extracellular-signal regu-
lated kinase (ERK) kinase (MEK)/ERK (Raf/MEK/ERK)
signaling pathway sorafenib exerts direct antiproliferative, apo-
ptotic and antiangiogenic effects on a variety of solid tumors as
well as leukemic cell lines [11]. The antiproliferative activity of
sorafenib varies from nanomolar to micromolar concentrations
depending on the oncogenic signaling pathways driving prolifer-
ation. The proapoptotic effects of sorafenib may vary among cell
lines and result from mechanism(s) of action that are only partially
elucidated. A commonly observed feature is the inhibition of
phosphorylation of the initiation factor eIF4E and downregulation
of the antiapoptotic protein myeloid cell leukemia-1 (Mcl-1)
[12,13], a Bcl-2 family member implicated in malignant hemato-
poietic cell survival. Downregulation of Mcl-1 by sorafenib is
associated with the release of cytochrome c from mitochondria
into the cytosol, caspase activation, and apoptotic cell death [14].
The ability of sorafenib to suppress tumor angiogenesis has been
well established and is likely due to the potent inhibition of the
proangiogenic vascular endothelial growth factor receptor
(VEGFR1)-1, VEGFR-2, VEGFR-3, and platelet-derived growth
factor receptor-ß [9]. In vivo, sorafenib exhibits antitumor activity
against a variety of human xenograft models of multiple
histological types, including melanoma, renal, colon, pancreatic,
hepatocellular, lung, and thyroid carcinomas, as well as acute
myelogenous leukemia [7,15–17]. Furthermore, sorafenib pro-
duced partial tumor regressions in mice bearing PLC/PRF/5
HCC and induced tumor regression in a breast cancer model
harboring B-Raf and K-Ras oncogenic mutations [18].
Several lines of in vitro evidence suggest that sorafenib might
have a role in the treatment of lymphomas by overcoming the
cytoprotective effects of ERK, and Mcl-1 and eventually targeting
oncogenic signaling pathways driving lymphomagenesis [19–23].
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Indeed, sorafenib-induced inhibition of the ERK1/2 pathway
might results in Bcl-XL downregulation [24], thus mimicking
rituximab-mediated effects on CD20-positive non-Hodgkin lym-
phoma cell lines [25]. Additionally, sorafenib might downregulate
Mcl-1 [14], which is implicated in resistance to anticancer drugs
and is overexpressed in a significant proportion of diffuse large B
cell lymphoma (DLBCL) and follicular lymphoma (FL) [26],
thereby restoring lymphoma cell sensitivity to apoptosis.
It was the aim of the present study to further investigate in
preclinical models both in vitro and in vivo the antitumor activity
and mechanism(s) of action of sorafenib using a panel of cell lines
representative of the heterogeneity of lymphoproliferative disor-
ders. Data reported herein demonstrate that pharmacologically
achievable concentrations of sorafenib inhibit the growth of
lymphoid cell lines of different histotypes, and suggest that both
antiangiogenic mechanism(s) as well as direct targeting of tumor
cells mediate the in vivo antilymphoma activity of sorafenib.
Materials and Methods
Reagents
Sorafenib (Bayer AG, Leverkusen, Germany, EU) was dissolved
in 100% dimethylsulfoxide (DMSO) to obtain a stock solution
(60 mg/ml). Working solutions (1006) were obtained by further
diluting in RPMI-1640 and were added to in vitro cultures at 1%
(v/v) to achieve a final DMSO concentration of 0.01%.
Cell lines and primary cells
SU-DHL-4V (DLBCL), Granta-519 [mantle cell lymphoma
(MCL)], HD-MyZ [Hodgkin lymphoma (HL)], and KMS-11
[multiple myeloma (MM)] cell lines were purchased from the
German Collection of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany, EU). Cell lines were cultured in RPMI-
1640 supplemented with 10% fetal bovine serum (FBS) and
periodically tested for mycoplasma contamination. Primary
DLBCL and MCL mononuclear cells (MNCs) were isolated at
the time of diagnostic work-up from the peripheral blood of
consenting patients. As assessed by flow cytometry, percentages of
neoplastic cells were always .95%.
Apoptosis and viable cell counting
Apoptotic cells were detected by annexin-V/propidium iodide
(PI) double staining and flow cytometry analysis, as previously
described [27]. Viable cells, i.e. annexin-V2/PI2 cells, were
counted with Flow-Count beads (Beckman Coulter, Milano, Italy,
EU) by flow cytometry. The proportion of viable cells was further
determined by an WST-based vitality assay following the
manufacturer’s recommendations (Biovision, Milpitas, CA, USA).
Measurement of DYm
Mitochondrial membrane depolarization was determined by
using the fluorescent probe TMRE and flow cytometry, as
previously described [28]. The fluorescent dye TMRE is
accumulated by mitochondria and as a results of mitochondrial
membrane depolarization, a shift to the left in the emission
spectrum by apoptotic cells can be detected.
Western blot analysis
Cell samples were homogenized in NP-40 lysis buffer (1% NP-
40, 20 mM Tris-HCl pH 8, 137 mM NaCl, 10% glycerol, 2 mM
EDTA, 1 mM sodium orthovanadate, 10 mg/mL aprotinin,
10 mg/mL leupeptin). Cell lysates were resolved by electrophoresis
on a 10% polyacrylamide gel and transferred to nitrocellulose
membranes. Immunocomplexes were visualized using an en-
hanced chemiluminescence Western blotting detection system
(Amersham Biosciences, Milano, Italy, EU). Blotting analysis was
performed using anti-Mcl-1, anti-phospho-MEK, -ERK,-AKT
S473, -S6, GSK-3 a/b, anti-p38a, -caspase-8 antibodies from Cell
Signaling (Danvers, MA, USA), anti-caspase-3 antibody (Santa
Cruz, San Diego, CA, USA), anti-caspase-9 and anti-poly(ADP-
ribose)polymerase (PARP) (B–D).
Phospho-MAPK proteome profiler array
Untreated and sorafenib-treated cells were washed with ice-cold
PBS and solubilized in NP-40 lysis buffer (1% NP-40, 20 mM
Tris-HCl pH 8, 137 mM NaCl, 10% glycerol, 2 mM EDTA,
1 mM sodium orthovanadate, 10 mg/mL aprotinin, 10 mg/mL
leupeptin). Cell lysates were centrifuged (14,000 rpm, 5 minutes,
4uC), and protein concentrations in the supernatants was
determined using the Bradford assay (Bio-Rad Laboratories).
Equal amounts of proteins (200 mg) from control and sorafenib-
treated cells were incubated with the human phospho-MAPK
array kit. The following kinases were detected: ERK1 (T202/
Y204), ERK2 (T185/Y187), c-Jun N-terminal kinase (JNK) pan
(T183/Y185, T221/Y223), p38a (T180/Y182), glycogen synthase
kinase (GSK)-3 a/b (S21/S9), GSK-3 b (S9), Akt pan (S473, S474,
S472), Akt1 (S473), Akt2 (S474), Akt3 (S472), p70 S6K (T421/
S424), and HSP27 (S78/S82). Phospho-MAPK array data
developed on X-ray films (Amersham Biosciences) following
exposure to chemiluminescent reagents were analyzed using the
open source imaging software ImageJ (http://rsb.info.nih.gov/ij/).
The assays were conducted in duplicate. A ratio of signal intensity
(sorafenib:control) was calculated for each of the four replicates
(two duplicates per assay) and transformed into a log value (base
10).
In vivo activity of sorafenib in tumor-bearing non-obese
diabetic/severe combined immunodeficient (NOD/SCID)
mice
Six- to eight-week-old NOD/SCID mice were purchased from
Charles River (Milano, Italy, EU) and xenografted with SU-DHL-
4V, Granta-519, HD-MyZ, or KMS-11 cell lines [27]. Mice were
housed under standard laboratory conditions according to our
institutional guidelines. Animal experiments were performed
according to the Italian laws (D.L. 116/92 and following
additions), which enforce the EU 86/109 Directive, and were
approved by the institutional Ethical Committee for Animal
Experimentation of the National Cancer Institute Foundation.
Tumor cells (56106 cells/mouse) were inoculated subcutaneously
(SC) in the right flank of each mouse. When tumor volume
reached approximately 100 mg in weight (6–13 days after tumor
inoculation), mice were randomly assigned to receive either a
short- or long-term treatment with sorafenib diluted in DMSO
(final concentration, 10% v/v) or control vehicle (DMSO 10%, v/
v). In preliminary experiments, mice injection with a 10% DMSO
solution failed to affect tumor cell signaling likely due to an in vivo
DMSO dilution as well as metabolism. The short-term treatment
consisting of intraperitoneal (IP) sorafenib (90 mg/kg) or DMSO
for 5 days was used to assess necrotic areas and tumor vascularity.
The long-term treatment consisted of sorafenib (90 mg/kg) or
DMSO 5 days per week for 3 weeks. The endpoint of the long-
term treatment was tumor weight. The tumors were measured
with calipers, and their weights were calculated using the formula:
(a6b2)/2, where a and b represented the longest and shortest
diameters, respectively. Antitumor efficacy was measured as tumor
growth inhibition (TGI) defined as [12(T/C)6100], where T and
C are the mean tumor weight in the treated and untreated control
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groups, respectively. Mice were monitored twice weekly and were
killed by cervical dislocation when they showed signs of terminal
illness, including hind leg paralysis, inability to eat or drink, and/
or moribund. Each experiment was performed on at least two
separate occasions, using five mice per experiment.
Analysis of tumor nodules
Tumor vasculature was analyzed by in vivo staining using
sulfosuccinimidyl-6-(biotinamido) hexanoate (sulfo-NHS-LC-bio-
tin, Thermo Fisher Scientific, Rockford, IL, USA) [27,29].
Biotinylated tumors were snap-frozen in isopentane in liquid
nitrogen. Tumor endothelial cells were then revealed by immu-
nohistochemistry using HRP-conjugated streptavidin (Dako,
Milano, Italy, EU) or immunofluorescence using Alexa Fluor
488-conjugated streptavidin (Invitrogen, Milano, Italy, EU).
Formalin-fixed, paraffin-embedded tumor nodules were stained
with hematoxylin and eosin (H&E) or processed for immunohis-
tochemistry with anti-mouse CD31 (Santa Cruz Biotechnology,
Inc., Heidelberg, Germany, EU) and anti-human Ki-67 (Dako).
Tumor necrosis was detected using TdT-mediated dUTP nick
end-labeling (TUNEL) staining (Roche, Milano, Italy, EU)
according to the manufacturer’s instructions. Positive signal was
revealed by 3,3-diaminibenzidine staining, and tumor sections
were then counterstained before analysis by light microscopy.
Analysis of stained sections
Entire tissue sections were acquired at 206magnification with
an automatic high-resolution scanner (dotSlide System, Olympus,
Tokyo, Japan) and subdivided into a collection of non-overlapping
red, green, and Blue (RGB) images in TIFF format (final
resolution, 3.125 pixels/mm). For necrosis quantification, images
were acquired at 26 magnification without further subdivision.
Image analysis was performed using the open source imaging
software ImageJ (http://rsb.info.nih.gov/ij/). Routines for image
analysis were coded in ImageJ macro language and executed on
RGB images without further treatment. Per each experimental
condition, at least three tissue sections from at least three different
tumor nodules were analyzed. Necrotic areas was evaluated on
TUNEL-stained sections as previously described [27]. Endothelial
cells were analyzed on cryosections from in vivo biotinylated mice
which were stained with HRP-conjugated streptavidin. Automatic
routines were validated by comparing results with those obtained
by visual counting of up to 10% of the total images.
Confocal microscopy
Confocal microscopy was performed as previously described
[27]. To detect tumor vessels, frozen sections were incubated with
Alexa Fluor 488-conjugated streptavidin. To detect pericytes and
tumor vessels, frozen sections were double stained with Alexa
Fluor 568-conjugated streptavidin and anti-mouse NG2. Forma-
lin-fixed, paraffin-embedded tumor nodules were sectioned at
1 mm and double-stained with anti-mouse CD31 (Santa Cruz
Biotechnology, Inc., Heidelberg, Germany, EU) and anti human/
mouse phospho-AKT (Ser473) or phospho-ERK1/2 (Cell Signal-
ing). CD31 expression was revealed by appropriate Alexa Fluor
568-conjugated secondary antibody (Invitrogen) and tumor/
endothelial p-AKT or p-ERK1/2 expression was revealed by
Alexa Fluor 488- conjugated secondary antibody (Invitrogen).
Nuclei were detected incubating sections with TO-PRO-3 nuclear
dye (Invitrogen). Fluorescence-stained sections were examined
under an epifluorescent microscope equipped with a laser confocal
system (MRC-1024, Bio-Rad Laboratories). Image processing was
carried out with LaserSharp computer software (Bio-Rad Labo-
ratories).
Statistical analysis
Statistical analysis was performed with the statistical package
Prism 5 (GraphPad Software, San Diego, CA, USA) run on a
Macintosh Pro personal computer (Apple Computer Inc.). To test
the probability of significant differences between untreated and
treated samples, the Student’s t test for unpaired data (two-tailed)
or two-way ANOVA were used, as appropriate. Tumor volume
data and proteome profiler array data were statistically analyzed
with two-way ANOVA, and individual group comparisons were
evaluated by Bonferroni’s multiple comparison test. Differences
were considered significant if p#0.05.
Results
Sorafenib reduces viable cell countings and triggers
apoptosis
The effects of sorafenib on cell proliferation were investigated in
vitro by performing dose-response and time-course experiments
using four cell lines representative of lymphoproliferative disorders
with different histotypes. Readout of these experiments included
viable cell countings and a WST-based cell proliferation assay.
Exposure to 5 mM sorafenib for 24 or 48 hours resulted in modest
cytostatic effects (Figure 1A, Figure S1). In contrast, in vitro
exposure to a clinically achievable concentration of sorafenib
(10 mM) [30] for 24–48 hours resulted in significant reductions of
cell viability (Figure 1B, Figure S1) (p#0.05 at least) with
cytotoxic effects being detected in SU-DHL-4V, Granta-519, and
KMS-11 cell lines and cytostatic effects being detected in HD-
MyZ cell line (Figure 1B).
To investigate whether sorafenib-induced antiproliferative
effects involved apoptosis, annexin-V/PI double staining was
performed (Figure 1B, Figure S2). Again, exposure to 5 mM
sorafenib had no effect on cell death, whereas exposure to 10 mM
sorafenib significantly increased (p#0.05 at least) cell death in all
cell lines but HD-MyZ cells. Sensitive cell lines showed a wide
degree of variability to sorafenib-induced apoptosis, with mean cell
death values of 35% (range, 30% to 40%) and 55% (range, 40% to
64%) following a 24- and 48-hour incubation, respectively
(Figure 1B). Upon sorafenib exposure, SU-DHL-4V and
Granta-519 cell lines but not KMS-11 cell line showed evidences
of caspase-independent apoptosis as suggested by the lack of
caspase activation and PARP cleavage (Figure 2A). To further
examine the molecular mechanisms whereby sorafenib triggers
apoptosis, we investigated whether loss of mitochondrial potential
was involved in sorafenib-induced cell death. Indeed, a potent
mitochondrial membrane depolarization could be detected in all
apoptosis-prone cell lines (Figures 2B–C), with loss of mitochon-
drial potential ranging from 58% to 94%.
Effects of sorafenib on primary DLBCL and MCL cells
Apoptotic activity of sorafenib was further evaluated by
analyzing its effect on primary cells purified from the peripheral
blood of DLBCL and MCL patients at diagnosis (Table 1). While
sorafenib-induced apoptosis could be detected in only 1 out of 3
MCL samples, apoptotic cell death was consistently observed in all
DLBCL samples.
Sorafenib affects phosphorylation of MAPK and PI3K/Akt
pathways
To analyze sorafenib’s effects on MAPK and PI3K/Akt
signaling pathways, we used a standard antibody array technology
allowing simultaneous analysis of all three major MAPKs,
including ERK1/ERK2, JNKs, and p38a, as well as the Akt
In Vivo Antilymphoma Activity of Sorafenib
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Figure 1. Antiproliferative and apoptotic effects of sorafenib. Following incubation with increasing doses of sorafenib, viable cell counts and
apoptotic cell death were assessed by annexin-V/PI double staining and flow cytometry analysis. (A) Viable cell counts upon exposure to 0 (&), 5 (%)
and 10 (N) mM sorafenib. Viable cells are expressed as fold increase (FI) of annexin-V2/PI2 cells after 24 and 48 hours of incubation with sorafenib as
compared to day 0. (B) Cell death following 24 (%) or 48 (&) hours sorafenib exposure. Percentages of cell death include annexin-V+/PI2 plus
annexin-V+/PI+ plus annexin-V2/PI+ cells. Values refer to four independent experiments. * p#0.001, u p#0.01, and ? p#0.05, compared to controls.
doi:10.1371/journal.pone.0061603.g001
In Vivo Antilymphoma Activity of Sorafenib
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isoforms, and the direct and indirect Akt targets GSK-3 a/b and
p70 S6 kinase 1 (p70S6K). Sorafenib (10 mM, 2 hours) affected
MAPK and PI3K/Akt signaling pathways in a rather heteroge-
neous manner (Figure 3A–C). As demonstrated by reduced
phosphorylation levels for ERK1/2 and p38a kinases, sorafenib
downregulated MAPK signaling in all cell lines. Analysis of PI3K/
Akt signaling revealed significantly reduced phosphorylation levels
of Akt1 and Akt2 in SU-DHL-4V and Granta-519 cell lines. These
lines also showed reduced phosphorylation levels of the direct and
indirect Akt targets GSK-3 a/b and p70S6K, revealing that
sorafenib may severely affect the PI3K/Akt pathway in some
lymphoma cell lines (Figure 3A–B). In contrast, PI3K/Akt
signaling was unaffected in the HD-MyZ, and KMS-11 cell lines.
Western blot analysis essentially confirmed the previous
antibody array results, further showing that sorafenib treatment
modulated MAPK and PI3K/Akt phosphorylation levels in a
rather heterogeneous manner depending on the different target
cells (Figure 3C). Consistent with sorafenib’s effect on the Raf/
MEK/ERK pathway, a time-dependent down regulation of MEK
and ERK phosphorylation could be detected in SU-DHL-4V,
HD-MyZ, and KMS-11 cell lines (Figure 3C). Additionally,
Figure 2. Mechanism of sorafenib-induced apoptosis. SU-DHL-4V, Granta-519, HD-MyZ and KMS-11 cells were treated with sorafenib (10 mM)
for 48 hours. (A) Cytosolic proteins were then separated by SDS-PAGE and analyzed by immunoblotting with anti-caspases-8, -9, -3, and anti-PARP.
CF, indicates cleaved fragments. (B) Loss of mitochondrial potential was measured using TMRE staining and flow cytometry. * p#0.001, compared to
controls. (C) Representative dot plots of mitochondrial membrane depolarization in untreated and sorafenib-treated cell lines.
doi:10.1371/journal.pone.0061603.g002
Table 1. Effects of sorafenib on primary DLBCL and MCL cells.
Case Diagnosis Annexin-V-/PI- (%)
DMSO 5 mM 10 mM
1 DLBCL 100 100 59
2 DLBCL 100 100 79
3 DLBCL 100 100 56
4 MCL 100 100 49
5 MCL 100 100 100
6 MCL 100 100 100
Freshly isolated blood MNCs from DLBCL and MCL patients were resuspended
(16106/ml) in RPMI-1640 supplemented with FBS (10%, v/v) and incubated
(24 hours, 37uC, 5% CO2) with sorafenib (5–10 mM). Controls were
supplemented with DMSO. At the end of the incubation, viable cell counts
(Annexin-V-/PI-) were evaluated by Flow-Count beads and Annexin-V/PI double
staining. Data are expressed as percent of control.
doi:10.1371/journal.pone.0061603.t001
In Vivo Antilymphoma Activity of Sorafenib
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e61603
Figure 3. Sorafenib treatment induced changes in survival signals in NHL cells. (A) To assess the effects of sorafenib, cells were exposed for
2 hours to control vehicle (DMSO) or sorafenib (10 mM). Shown are data from one of two independent experiments. The chemiluminescence signal
intensity of individual spots was analyzed using the open source imaging software ImageJ (http://rsb.info.nih.gov/ij/). The assays were conducted in
duplicate. A ratio of signal intensity (sorafenib:control) was calculated for each of the four replicates (two duplicates per assay) and transformed into a
log value (base 10). * p#0.001, and u p#0.01, compared to controls. (B) Shown are data from one of two independent experiments. Representative
proteome profiles of control and sorafenib-treated cell lines. The position of the antibodies (double spots for each antibody) relative to the relevant
protein kinases is shown. The chemiluminescence signal intensity of individual spots was analyzed using the open source imaging software ImageJ
(http://rsb.info.nih.gov/ij/). 1 = positive control; 2 = p70 S6 kinase; 3 =Akt pan; 4 =Akt 2; 5 =Akt 1; 6 =GSK-3 a/b; 7 = p38 a; 8 = JNK pan; 9 = ERK2; and
10 = ERK1. (C) Immunoblots of extracts from SU-DHL-4V, Granta-519, HD-MyZ and KMS-11 cells treated with control vehicle (DMSO) or sorafenib
(10 mM) for the indicated time periods showed consistent downregulation of p-38a phospho-ERK, phospho-MEK, phospho-Akt, phospho-S6,
phospho- GSK-3 a/b and Mcl-1. Equal protein loading was confirmed by blotting for b-actin.
doi:10.1371/journal.pone.0061603.g003
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exposure to sorafenib resulted in a time-dependent down
regulation of p-38a in all cell lines. SU-DHL-4V and Granta-
519 cells demonstrated constitutive phosphorylation of Akt, which
was completely inhibited by sorafenib in a time-dependent
manner. Phosphorylation of S6, downstream target proteins of
Akt, was also markedly inhibited in all cell lines (Figure 3C).
Upon sorafenib exposure, expression of Mcl-1 was markedly down
regulated in SU-DHL-4V, HD-MyZ and KMS-11 cells, whereas
no effect was observed in Granta-519 cells (Figure 3C).
Sorafenib inhibits tumor cell proliferation and
angiogenesis
NOD/SCID mice inoculated subcutaneously with SU-DHL-
4V, Granta-519, HD-MyZ, or KMS-11 cells, received a 15-day
treatment with sorafenib (90 mg/kg/day, 5 days per week for 3
weeks) or vehicle control. Treatment was started when tumor
volumes reached approximately 100 mg in weight (i.e., 6–13 days
after tumor inoculation). Sorafenib treatment resulted in modest
effects on the growth of SU-DHL-4V, Granta-519, and KMS-11
xenografts, as shown by TGI values of 37%, 39%, and 53%,
respectively, whereas it substantially affected the growth of HD-
MyZ xenograft, resulting in a 71% TGI (Figure 4A). These
Figure 4. Effect of sorafenib on tumor growth. (A) NOD/SCID mice bearing SC tumor nodules 100 mg in weight were randomly assigned to
receive a 15-day treatment with sorafenib (&) (90 mg/kg/day, 5 days per week over 3 weeks) or control vehicle (DMSO) (N). Mice were checked twice
weekly for tumor appearance, tumor dimensions, body weight, and toxicity. Mean (6 SEM) values refer to at least two independent experiments,
using 5 mice per experiment. Treatment initiation is indicated by horizontal black lines. * p#0.001 and u p#0.01 compared to controls. (B) Ki-67
staining of lymphoma tumor treated with sorafenib (90 mg/kg/day, 5 days) or control vehicle (DMSO). In the Ki-67-stained section, brown staining
represents positive signals within the tumors (blue cells are the negative, living cells). Objective lens, original magnification: 0.75 NA dry objective,
206. Scale bar: 50 mm.
doi:10.1371/journal.pone.0061603.g004
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findings were paralleled by a strong decrease of Ki-67 expression
in tumor cells (Figure 4B), suggesting that sorafenib indeed
inhibited tumor cell proliferation. However, such an antiprolifer-
ative effect was not associated with an increase of tumor cell
apotosis, as evaluated by TUNEL staining (data not shown),
suggesting that the effect of sorafenib on tumor cell growth was
cytostatic rather than cytotoxic.
We then evaluated the effects of sorafenib on tumor vasculature
by using a sulfo-NHS-LC-biotin-based in vivo assay that allows a
detailed qualitative and quantitative analysis of tumor vasculature
[29]. Tumor vessel density was assessed by quantifying the
percentage of biotinylated cells, i.e., the percentage of the entire
tissue section occupied by endothelium. Reduction of tumor
vasculature was calculated within viable tumor areas only while
excluding necrotic areas. Regardless of the lymphoma subtype,
tumor vasculature in control mice was abundant, tortuous, and
evenly distributed throughout the tumor, which thus appeared well
vascularized (Figure 5A). Extensive vascularization is likely due to
the upregulation of VEGFR-2 expression by tumor cells and
tumor endothelium and the concomitant production of VEGF by
tumor cells (data not shown) [31].
In control mice, vascular density resulted in mean values of
endothelial areas ranging from 7% to 11% of the total tumor area.
Upon a 5-day sorafenib treatment, all tumors showed an average
50% inhibition of tumor vessel density (Figure 5A). In fact, as
compared to mice receiving vehicle control, sorafenib significantly
Figure 5. Effect of sorafenib on tumor vasculature. (A) Mice treated with sorafenib (90 mg/kg) or control vehicle (DMSO) were in vivo
biotinylated with sulfo-NHS-LC-biotin, and tumor vasculature was revealed by staining sections with Alexa Fluor 488-streptavidin (upper panel,
objective lens, original magnification: 1.0 NA oil objective, 406). CD31-stained tumor paraffin sections are shown for comparison (lower panel,
objective lens, original magnification: 0.75 NA dry objective, 206). (B) Quantification of endothelial area on entire tissue sections was achieved with
ImageJ software. The reduction of vessel density detected in sorafenib-treated nodules was calculated by assessing only viable areas of tissue
sections while excluding necrotic areas. The boxes extend from the 25th to the 75th percentiles, the lines indicate the median values, and the whiskers
indicate the range of values.
doi:10.1371/journal.pone.0061603.g005
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reduced mean endothelial areas of SU-DHL-4V (11% vs 6%,
p#0.0001), Granta-519 (8% vs 3%, p#0.0001), HD-MyZ (7% vs
3%, p#0.0001), and KMS-11 (9% vs 5%, p#0.0001) nodules
(Figure 5B). The potent sorafenib-induced inhibition of tumor
vascularization was further confirmed by staining tumor sections
with the endothelial cell marker CD31 (Figure 5A).
In sorafenib-treated tumors, vessels appeared smaller in length,
lacking in sproutings and much less arborized and dishomogen-
eously distributed throughout tumor tissue as compared to vehicle-
treated animals (Figure 5A) [32], suggesting that in contrast with
other antiangiogenic drugs, sorafenib has no effect on vessel
normalization [33]. To further investigate this issue, tumor
sections were co-stained for both tumor vasculature with Alexa
Fluor 568-conjugated streptavidin, and pericytes with anti-NG2
antibody. After sorafenib treatment, confocal microscopy analysis
showed a marked reduction of pericytes in SU-DHL-4V and HD-
MyZ xenografts, whereas no difference was observed in Granta-
519 and HD-MyZ xenografts, further supporting no activity of
sorafenib on vessel normalization (Figure 6).
In vivo anti-tumor mechanism(s) of sorafenib were additionally
investigated by analyzing Akt and ERK1/2 phosphorylation in
sorafenib-treated tumor cells and tumor vasculature (Figure 7).
Tumor and vascular ERK1/2 phosphorylation was unaffected in
SU-DHL-4V and Granta-519 cell lines, whereas it was strongly
Figure 6. Effects of sorafenib on pericytes. Mice treated with sorafenib (90 mg/kg/die, 5 days) or control vehicle (DMSO) were in vivo
biotinylated with sulfo-NHS-LC-biotin. SU-DHL-4V, Granta-519, HD-MyZ and KMS-11 tumor vasculature was revealed by staining sections with Alexa
Fluor 568-streptavidin (red). Tumor sections were stained with NG-2 (green) followed by AlexaFluor 488-conjugated secondary antibody for indirect
immunofluorescent detection of pericytes. Nuclei were detected with DAPI nuclear dye (blue). Representative images are shown. Objective lens,
original magnification: 1.0 NA oil objective, 406. Scale bar: 100 mm.
doi:10.1371/journal.pone.0061603.g006
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reduced in HD-MyZ and KMS-11 cell lines. Tumor and vascular
Akt phosphorylation was reduced in SU-DHL-4V, Granta-519
and HD-MyZ cell lines, but not in KMS-11 cell line. Thus, HD-
MyZ xenograft showed a combined inhibition of ERK1/2 and
Akt phosphorylation on both tumor and endothelial cells, whereas
the remaining lymphoma xenografts showed a selective inhibition
of either ERK1/2 or Akt pathways on both tumor and vascular
cells (Figure 7). Notwithstanding the strong inhibition of ERK1/2
and/or Akt phosphorylation on vascular cells, we did not detect
any increase in tumor endothelial cell apoptosis, as evaluated by
CD31/TUNEL double-staining (data not shown).
Despite apoptosis was not a prominent features of tumor or
endothelial cells in sorafenib-treated mice, tumor sections from
these animals showed large areas of non-hemorrhagic tumor
necrosis by hematoxilyn/eosin as well as TUNEL staining
(Figure 8A), suggesting that hypoxic conditions subsequent to
tumor vessel inhibition might have triggered tumor destruction. As
compared to controls, sorafenib significantly increased necrotic
areas in mice bearing SU-DHL-4V (7% vs 13%, p#0.0001),
Granta-519 (7% vs 17%, p#0.004), HD-MyZ (18% vs 45%,
p#0.0001), and KMS-11 (2% vs 8%, p#0.0001) xenografts
(Figure 8B).
Discussion
Data reported herein using four cell lines representative of
different lymphoproliferative disorders show that sorafenib may
exert antilymphoma activities that are likely mediated by a variety
of mechanism(s), including antiproliferative effects on tumor cells
as well as antiangiogenic effects. These findings significantly
extend the spectrum of tumors that sorafenib targets and are
consistent with previously reported results showing efficacy of
sorafenib in multiple tumor xenograft models [7,15–17].
In vitro, clinically achievable concentrations of sorafenib (5–
10 mM) [30] induced a marked inhibition of MAPK and/or
PI3K/Akt signaling as well as Mcl-1 in all cell lines, resulting in a
significant reduction of cell proliferation and/or induction of
apoptosis. Sorafenib affected both MAPK and PI3K/Akt signaling
in essentially all analyzed cell lines, with PI3K/Akt signaling being
markedly affected in SU-DHL-4V and Granta-519 cell line. In
vivo, sorafenib has previously been reported to inhibit the growth
of a wide variety of human tumor xenografts in mice [7,15–17].
Our data obtained in four xenograft models of lymphoma
demonstrate that the potent antiangiogenic activity of sorafenib,
eventually combined with its marked inhibition of lymphoma cell
Figure 7. Sorafenib-induced inhibition of Akt and ERK phosphorylation in tumor and endothelial cells. SU-DHL-4V, Granta-519, HD-MyZ
and KMS-11 tumor nodules growing subcutaneously in mice treated with sorafenib (90 mg/kg) or control vehicle (DMSO) for 5 days were excised
3 hours after the last treatment, fixed in formalin and embedded in paraffin. Tumor sections were double-stained with CD31 (red) and phospho-ERK
1/2 (green) or phospho-Akt (green) followed by the appropriate AlexaFluor 568- or 488-conjugated secondary antibody for indirect
immunofluorescent detection of the corresponding antigen. Nuclei were detected with TO-PRO-3 nuclear dye (blue). Arrows indicate phospho-
ERK 1/2 or pospho-Akt expression by endothelial cells; arrowheads indicate phospho-ERK 1/2 or pospho-Akt expression by tumor cells.
Representative images are shown. Objective lens, original magnification: 1.0 NA oil objective, 406. Scale bar: 50 mm.
doi:10.1371/journal.pone.0061603.g007
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Figure 8. Sorafenib induces in vivo tumor necrosis. (A) H&E and TUNEL staining of lymphoma tumor treated with sorafenib (90 mg/kg) or
control vehicle (DMSO). In the TUNEL-stained section, brown staining represents positive signals within the tumors (blue cells are the negative, living
cells). Objective lens, original magnification: 0.08 NA dry objective, 26. (B) Quantification of necrotic areas on entire tissue sections using ImageJ
software. Percentage of necrosis was calculated by the following formula: (necrotic area/total tissue area)6100. The boxes extend from the 25th to the
75th percentiles, the lines indicate the median values, and the whiskers indicate the range of values.
doi:10.1371/journal.pone.0061603.g008
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proliferation, induces a relevant tumor destruction as shown by
large areas of tumor necrosis detected in sorafenib-treated mice.
According to previously reported studies, an optimal biological
dose of sorafenib (90 mg/kg/day) was choosen for our in vivo
experiments [9,18,34]. Sorafenib dose resulting in antitumor
activity in our xenograft models (90 mg/kg/day) roughly equals to
600 mg/day in humans and compares well with the standard
sorafenib daily dose used in clinical trials. The treatment dose used
in our experiments is expected to produce plasma drug
concentrations in the range of pharmacologically achievable
concentrations of sorafenib, i.e., 5 to 15 mM, that are consistently
detected in patients receiving the standard sorafenib daily dose of
800 mg [4,5,17,30].
While a 5-day treatment with sorafenib induced an average
50% inhibition of tumor angiogenesis and extensive tumor
necrosis, biologically significant effects on the volume of lympho-
ma xenografts could only be observed in one of four xenografts
(i.e., HD-MyZ) and required a long-term sorafenib treatment.
Indeed, the limited effects of sorafenib on the volume of
lymphoma xenografts closely resemble the findings frequently
reported in patients treated with sorafenib who may experience a
clinical benefit in the absence of any tumor volume reduction
[3,35].
Analysis of tumor xenografts showed a substantial reduction of
Ki-67 expression, as well as inhibition of phospho-Akt and/or
phospho-ERK1/2 levels, suggesting that sorafenib-mediated
lymphoma growth inhibition also involves a direct inhibition of
cancer cell proliferation. However, analysis of tumor nodules from
mice receiving a 5-day sorafenib treatment revealed a marked
reduction of tumor angiogenesis, eventually associated with
inhibition of vascular phospho-Akt and/or phospho-ERK1/2,
thus suggesting that inhibition of angiogenesis is likely to play a key
role in triggering the antitumor activity of sorafenib. Indeed,
angiogenesis inhibition almost certainly represents a primary effect
of sorafenib treatment rather than being secondary to tumor cell
loss and reduced production of angiogenic factors. In fact,
inhibition of tumor angiogenesis was detected in non-necrotic
areas, suggesting that inhibition of tumor vasculature was the first
event triggered by sorafenib, subsequently leading to the
generation of extensive tumor necrosis due to hypoxic conditions.
Alternatively, if tumor cell loss would have preceded reduction of
angiogenesis, tumor vessel density would not be expected to
decrease and should result unchanged or possibly increased.
Taken together, these data strongly support that sorafenib acts
primarily as an antiangiogenic agent, as shown by the marked
tumor vessel reduction, but it also directly affects lymphoma cells,
as shown by Ki-67 inhibition.
It has been proposed that one of the mechanisms by which
antiangiogenic agents mediate their effect is to transiently
‘‘normalize’’ tumor vasculature, resulting in attenuation of
hyperpermeability, increased vascular pericyte coverage, reduction
in tumor hypoxia and interstitial fluid pressure [36]. The results of
our studies however, show that administration of sorafenib results
in a decrease of vasculature, leading to elevated level of tumor
necrosis with the absence of vessel normalization as detected by
vessel morphological features as well as number of pericytes.
Although vessels leakiness poses a challenge for drug delivery [37],
at the same time, lack of pericytes makes the vessels susceptible to
antiangiogenic therapies [38]. Sorafenib may therefore improve
anti-angiogenic therapy in lymphoma by targeting both endothe-
lial cells as well as their supporting pericytes.
The best in vivo antitumor response to sorafenib, i.e., a 70%
TGI, was detected in NOD/SCID mice bearing HD-MyZ
xenografts that showed a marked inhibition of both tumor and
vascular ERK1/2 and Akt phosphorylation, suggesting that the
concomitant inhibition of MAPK and PI3K/Akt signaling is
required to achieve an optimal antilymphoma activity. In contrast,
modest in vivo responses, ranging from 35% to 50% TGIs, were
observed in mice bearing SU-DHL-4V, Granta-519 or KMS-11
xenografts that were characterized by a selective in vivo inhibition
of either ERK1/2 or Akt signaling. Overall, MAPK, PI3K/Akt
and Mcl-1 signaling pathways appear to be critical determinants
mediating the in vivo antitumor response to sorafenib [12,14,39].
Human lymphomas harbor multiple genetic and epigenetic
alterations leading to deregulation of multiple pathways and
cellular processes. Our data as well as those of others [19–22]
suggest that the therapeutic armamentarium today available for
human lymphomas might also include sorafenib mainly due to its
antiangiogenic properties along with its antiproliferative and
signaling inhibitory activities eventually associated with down
modulation of Mcl-1 expression [31,40,41]. As a single agent,
sorafenib might preferentially act as an inducer of tumor necrosis,
whereas it might enhance the efficacy of radio-chemotherapy due
to its effects on vessel normalization. In conclusion, our results
provide evidence that sorafenib may be a potentially interesting
molecule for the treatment of lymphoproliferative disorders mainly
due to its antiangiogenic properties.
Supporting Information
Figure S1 Cell growth inhibition of sorafenib toward
NHL cells. NHL cells were treated with the indicated
concentrations of sorafenib for 24–48 hours. Cell viability was
measured using WST assays. * p#0.0001 and ? p#0.001
compared to controls.
(TIF)
Figure S2 Sorafenib cytotoxicity. Cell death was assessed by
annexin-V/PI double staining and flow cytometry analysis.
Representative dot plots of cell death in untreated and
sorafenib-treated (5–10 mM) cell lines after 48 hours of exposure.
(TIF)
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